tiprankstipranks
Aeterna Zentaris issued notice of allowance for USPTO for macimorelin patent
The Fly

Aeterna Zentaris issued notice of allowance for USPTO for macimorelin patent

The Company announced that the USPTO has issued a Notice of Allowance for Aeterna’s U.S. patent application No. 17/375,709 titled, "Use of Macimorelin in Assessing Growth Hormone Deficiency in Children." The Company anticipates the issue of the formal registration of this U.S. patent application in the coming months. AEZS-130-P02, Aeterna’s pivotal Phase 3 safety and efficacy study evaluating macimorelin for the diagnosis of CGHD, remains ongoing. Most clinical sites in the U.S. as well as European countries are open for patient recruitment.

Published first on TheFly

See the top stocks recommended by analysts >>

Read More on AEZS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles